Semaglutide 2.4 mg linked to increased gallbladder adverse events in pooled STEP trials analysis

Obesity and type 2 diabetes are global health crises requiring effective treatments. Semaglutide, a potent GLP-1 receptor agonist, has demonstrated significant efficacy in weight management and glycemic control. However, GLP-1R agonists have been associated with an increased risk of gallbladder-related adverse events, including cholelithiasis and cholecystitis. Understanding the specific incidence with the higher 2.4 mg dose of semaglutide is crucial for patient safety and clinical guidance, especially given its widespread use.

This study conducted a pooled analysis of safety data from multiple placebo-controlled STEP clinical trials. The researchers evaluated the incidence of gallbladder-related adverse events in patients receiving semaglutide 2.4 mg compared to those on placebo. The analysis aggregated safety data from trials investigating semaglutide 2.4 mg for weight management in overweight or obese adults, assessing outcomes such as cholelithiasis, cholecystitis, and related surgical interventions. This approach allowed for a comprehensive assessment of adverse event profiles across a large patient population.

The pooled analysis of placebo-controlled STEP trials consistently demonstrated an elevated risk of gallbladder-related adverse events in patients treated with semaglutide 2.4 mg compared to those receiving placebo. These events primarily encompassed cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), with some cases progressing to require cholecystectomy. While specific incidence rates and statistical significance values are not detailed in the available information, the overall conclusion points to a clear and reproducible pattern of heightened risk with the higher dose.

The findings highlight that the incidence of gallbladder-related adverse events was notably higher in the semaglutide 2.4 mg group, indicating a significant safety consideration for this therapeutic dose.